Literature DB >> 19057612

Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO.

J Gadzinowski1, K Kowalska, D Vidyasagar.   

Abstract

The objective of the study was to compare the effectiveness of surfactant treatment either by bolus or surfactant lung lavage followed by inhaled nitric oxide (iNO) therapy in infants with meconium aspiration syndrome (MAS) complicated by persistent pulmonary hypertension (PPHN). In this study, thirteen infants with diagnosis of MAS and PPHN were first treated with conventional respiratory support. Then between 2 and 22h of life they were randomized either to bolus surfactant treatment (n=6) or surfactant lung lavage (SLL, n=7) treatment. Then all infants were treated with iNO therapy. The groups were compared with regard to their clinical course: changes in PaO(2), FiO(2), MAP, OI, A-a oxygen gradient, duration of iNO therapy, length of ventilation and hospitalization. Complications and mortality were also compared. The results showed that infants treated with SLL had significant improvements in oxygenation, decreases in MAP and A-a gradients. But there were no significant differences in duration of ventilation, iNO treatment, length of hospitalization or complications. In conclusion these data show no advantage of SLL therapy over bolus surfactant treatment in infants with MAS complicated by PPHN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19057612     DOI: 10.1038/jp.2008.163

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  6 in total

Review 1.  Surfactant for meconium aspiration syndrome in term and late preterm infants.

Authors:  Amr I El Shahed; Peter A Dargaville; Arne Ohlsson; Roger Soll
Journal:  Cochrane Database Syst Rev       Date:  2014-12-14

Review 2.  An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.

Authors:  Paul O Nkadi; T Allen Merritt; De-Ann M Pillers
Journal:  Mol Genet Metab       Date:  2009-02-04       Impact factor: 4.797

Review 3.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

Review 4.  Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review.

Authors:  Mohammed Puthiyachirakkal; Maroun J Mhanna
Journal:  Front Pediatr       Date:  2013-09-02       Impact factor: 3.418

Review 5.  Surfactant therapy and antibiotics in neonates with meconium aspiration syndrome: a systematic review and meta-analysis.

Authors:  C K Natarajan; M J Sankar; K Jain; R Agarwal; V K Paul
Journal:  J Perinatol       Date:  2016-05       Impact factor: 2.521

Review 6.  Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps.

Authors:  Daniele De Luca; Paola Cogo; Martin C Kneyber; Paolo Biban; Malcolm Grace Semple; Jesus Perez-Gil; Giorgio Conti; Pierre Tissieres; Peter C Rimensberger
Journal:  Crit Care       Date:  2021-02-22       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.